Susana Garcia
Adult Health · Stroudsburg, PANPI 1750878567
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,475 of the $14,537 with a category attached, or 65.2%. 9 manufacturers reported payments, led by AbbVie at 49.7% of the total. Reporting peaked in 2024 at $6,509 and has fallen 79.0% since, to $1,366 in 2025. Among adult health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $63.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Gilead$6K
- Viiv Healthcare Company$785
- Merck$175
- Janssen Products, LP$99
- Alkermes, Inc.$98
- plus $128 from 3 others
What the payments were for
- Speaking & faculty fees$9,47565%
- Travel & lodging$1,54411%
- Food & beverage$3,41924%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $7,231 |
| Gilead | 90 | $6,021 |
| Viiv Healthcare Company | 60 | $785 |
| Merck | 10 | $175 |
| Janssen Products, LP | 1 | $99 |
| Alkermes, Inc. | 4 | $98 |
| Johnson & Johnson(2 entities) | 3 | $66 |
| Theratechnologies Inc. | 2 | $45 |
| Indivior Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,537 in reported general payments places this provider in the 95th percentile of 899 adult health providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 63 | $244,516 |
| DescovyEmtricitabine/Tenofov Alafenam | 88 | $185,449 |
| TivicayDolutegravir Sodium | 14 | $40,363 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 16 | $691 |
| ValacyclovirValacyclovir Hcl | 11 | $495 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $6,021 | $429,964151 claims |
| Viiv Healthcare CompanyTivicay | $785 | $40,36314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Stroudsburg
- Beth SandyPhiladelphia$924K
- Jennifer MondilloSchwenksville$396K
- Diane NewmanPhiladelphia$343K
- Elizabeth FaustDouglassville$342K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
- Bethann MallonBlue Bell$65K
- Catherine HoldsworthPhiladelphia$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.